Research Paper Volume 14, Issue 23 pp 9617—9631
A circadian rhythm-related biomarker for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma
Figure 3. Clinical significance of the newly-established signature. (A–C) The low-risk cohort showed an improved prognosis than its counterpart in the discovery cohort, the validation cohort, and GSE30219. (D–F) The risk levels were significantly augmented in patients of higher TNM staging.